Table 1. Mapped human CD8+ T-cell epitopes in the conserved regions of HIVconsv.
| Expanding 15-mer peptide | Mapped epitope | Immune Epitope | Predicted HLA | Confirmed | New | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Number | Sequence | VID | Name | Sequence | Database (HLA) | HLA | % rank | Aff (nM) | HLA | epitope |
| HC031 | CTERQANFLGKIWPS | 421 | TL8 | TERQANFL | B*40:02 | B*40:02 | 1.5 | 129 | ND | |
| TK10 | TERQANFLGK | ND | B | |||||||
| CK11 | CTERQANFLGK | not reported | A*11:01 | 0.8 | 55 | ND | B | |||
| HC049 /HC050 | KNFPISPIETVPVKLK /SPIETVPVKLKPGMD | 406 | IL8 | IETVPVKL | B*40:01 | B*40:01 | 1.0 | 89 | ND | |
| B*44:03 | 1.5 | 923 | ND | |||||||
| HC078 | YFSVPLDEGFRKYTA | 421 | SK10 | SVPLDEGFRK | A11 | A*11:01 | 3.0 | 242 | A*11:01 | A |
| VK9 | VPLDEGFRK | not reported | NP | - | - | C*12:03 | A | |||
| HC078 / HC079 | YFSVPLDEGFRKYTA / PLDEGFRKYTAFTIP | 417 | VY10 | VPLDEGFRKY | B*35:01 | B*35:01 | 0.5 | 47 | B*35:01 | |
| HC080 | GFRKYTAFTIPSINN | 411 | TI8 | TAFTIPSI | A*02:01/B*51:01 | B*51:01 | 0.8 | NA | DNC | |
| C*03:03 | 5.0 | 459 | DNC | |||||||
| YI9 | YTAFTIPSI | A*02:01 | A*02:01 | 2.0 | 68 | DNC | ||||
| B*51:01 | 3.0 | NA | DNC | |||||||
| KI10 | KYTAFTIPSI | A2 | C*07:01 | 3.0 | NA | DNC | ||||
| HC081 | YTAFTIPSINNETPG | 415 | TG11 | TIPSINNETPG | not reported | NP | - | - | ND | B |
| PG9 | PSINNETPG | not reported | NP | - | - | DNC | B | |||
| YI9 | YTAFTIPSI | A*02:01 | A*02:01 | 2.0 | 68 | ND | ||||
| C*07:02 | 4.0 | NA | ND | |||||||
| HC088 | GSPAIFQSSMTKILE | 409 | SK11 | SPAIFQSSMTK | B07 | NP | - | - | B*07:02 | A |
| IL10 | IFQSSMTKIL | Not reported | NP | - | - | ND | B | |||
| SK11 | SPAIFQSSMTK | A11 | NP | - | - | A*11:01 | A | |||
| 421 | SM9 | SPAIFQSSM | not reported | B*35:03 | 0.2 | NA | DNC | B | ||
| AK9 | AIFQSSMTK | A*11:01 | A*11:01 | 0.05 | 8.0 | A*11:01 | ||||
| HC091 | ILEPFRAQNPEIVIY | 410 | FY11 | FRAQNPEIVIY | not reported | NP | - | - | ND | B |
| RY10 | RAQNPEIVIY | not reported | A*30:02 | 1.5 | 114 | ND | B | |||
| AY9 | AQNPEIVIY | A*30:02 | A*30:02 | 1.0 | 77 | ND | ||||
| HC092 / HC093 | FRAQNPEIVIYQYMDKK / KNPEIVIYQYMDDLYV | 410 | NY9 | NPEIVIYQY | B18 | B*18:01 | 0.8 | 189 | DNC | |
| PM9 | PEIVIYQYM | not reported | B*18:01 | 3.0 | 1138 | B*18:01 | A | |||
| ED9 | EIVIYQYMD | not reported | NP | - | - | B*18:01 | A | |||
| HC093 | KNPEIVIYQYMDDLYV | 411 | VV11 | VIYQYMDDLYV | A*02:01 | A*02:01 | 1.0 | 31 | A*02:01 | A |
| 415 | IV10 | IYQYMDDLYV | A*02:01 | NP | - | - | A*02:01 | |||
| 416 | YV9 | YQYMDDLYV | A*02:01 | A*02:01 | 0.4 | 10. | A*02:01 | |||
| 418 | QV8 | QYMDDLYV | not reported | NP | - | - | A*02:01 | B | ||
| HC102 | KQVDRMRIRTWKSLVK / | 403 | RK10 | RIRTWKSLVK | not reported | A*30:01 | 0.03 | 3 | A*30:01 | A |
| IK9 | IRTWKSLVK | not reported | NP | - | - | A*30:01 | A | |||
| HC103 | MRIRTWKSLVKHHLT | 418 | IH10 | IRTWKSLVKH | not reported | NP | - | - | B*27:05 | A |
| HC135 | KLVSQGIRKVLFLDG | 416 | KV10 | KLVSQGIRKV | not reported | A*02:01 | 3.0 | 210 | A*02:01 | A |
| 418 | KLVSQGIRKVLF | not reported | NP | ND | B | |||||
| HC139 | DKAQAKEIVASCDKC | 404 | AC11 | AKEIVASCDKC | not reported | NP | - | - | ND | B |
| AD9 | AKEIVASCD | not reported | NP | - | - | ND | B | |||
| HC145 | GQVDCSPGIWQLDCTH | 404 | GH9 | GIWQLDCTH | not reported | NP | - | - | ND | B |
| HC164 | VQMAVFIHNFKRKGGI | 404, 410 | IG9 | IHNFKRKGG | not reported | NP | - | - | ND | B |
| HC176 | VVPRRKAKIIRDYGK | 413 | VI10 | VVPRRKAKII | not reported | NP | - | - | B*08:01 | A |
| RK11 | RKAKIIRDYGK | not reported | NP | - | - | B*08:01 | A | |||
| KK8 | KIIRDYGK | not reported | A*03:01 | 0.8 | 183 | B*08:01 | A | |||
VID–volunteer identification number; K or KK–lysines added to the ‘parental’ 15-mer peptides for solubility; Immune Epitope Database (www.iedb.com)—T-cell epitope prediction for HLA binding according to HLArestrictor with NetMHCpan version 2.4: % rank–strong binding peptides <0.5, intermediate binding peptides 0.5–2.0 and >2.0 weak binding peptides (% ranks over 5.0 are not shown); Aff (nM)–affinity of peptide for HLA as approximate thermodynamic constant KD (high affinity <50 nM, intermediate affinity 50–500 nM and low affinity 5,000–500 nM); NP–not predicted; NA–no available; ND–not done; DNC–done, but no HLA-restriction confirmed. A–‘A-list’ candidate; B–‘B-list’ candidate.